Top Markets
#1 Seeker Seeker +18.80%
#2 EXOD EXOD +9.04%
#3 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.47%
#4 Arowana Arowana +5.88%
#5 MetaDAO MetaDAO +4.67%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +4.02%
#7 Mina Protocol Mina Protocol +3.88%
#8 Pons Pons +3.00%
#9 Solstice Solstice +2.88%
#10 Official Trump Official Trump +2.75%
Coin of the day
Seeker Seeker
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rang in Aktien #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Aktienkurs
$64.97
Zuletzt synchronisiert: 2024-05-20
Marktkapitalisierung
$1.97B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategorie

Healthcare
P/B-Verhältnis für Alpine Immune Sciences, Inc. (ALPN)
P/B-Verhältnis zum August 2026 TTM: 9.91
Laut den neuesten Finanzberichten und dem Aktienkurs von Alpine Immune Sciences, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 9.91. Am Ende des Jahres 2022 lag das P/B-Verhältnis bei 1.37.
P/B-Verlauf für Alpine Immune Sciences, Inc. von 2012 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 9.91 240.41%
2023 2.91 112.16%
2022 1.37 -53.07%
2021 2.92 -30.87%
2020 4.22 76.50%
2019 2.39 109.27%
2018 1.14 24.25%
2017 0.92 46.95%
2016 0.63 -27.94%
2015 0.87 -110.05%
2014 -8.64 479.51%
2013 -1.49 0.00%
2012 0.00 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -35.98%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -36.99%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -74.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -62.56%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH